
AbbVie rose 26.1% from $234.00 to a 1-year high of $295.03, ahead of the S&P 500's +13.3%. Its worst day was Mar 18 (−5.2%), and its low came Apr 27 at $197.38.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
UBS rated AbbVie Neutral and lifted its price target from $220.00 to $240.00; shares rose 4.2%.
+4.2% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
EPS of $2.71 beat the $2.66 estimate on $16.6B revenue (est. $16.4B); Q1 revenue guidance of $14.7B against the $15.0B consensus.
−3.8% · S&P 500 −0.5%
AbbVie shares fell 5.2%, while the S&P 500 fell 1.4%.
−5.2%, the year's worst day · S&P 500 −1.4%
EPS of $2.65 missed the $2.66 estimate on $15.0B revenue (est. $14.7B); FY revenue guidance of $67.3B against the $67.1B consensus.
+3.1% · S&P 500 0.0%
AbbVie shares rose 6.2%, while the S&P 500 fell 0.3%.
+6.2%, the year's best day · S&P 500 −0.3%
AbbVie shares rose 4.0%, while the S&P 500 fell 0.1%.
+4.0% · S&P 500 −0.1%
AbbVie shares rose 4.2%, while the S&P 500 fell 0.5%.
+4.2% · S&P 500 −0.5%
EPS of $3.65 missed the $3.77 estimate on $17.0B revenue (est. $16.8B); FY revenue guidance of $67.6B against the $67.3B consensus.
−2.5% · S&P 500 +0.7%
EPS of $3.82 beat the $3.77 estimate on $17.4B revenue (est. $17.4B); Q4 revenue guidance of $18.4B against the $18.3B consensus.
+1.4% · S&P 500 −1.8%
Where it ended: a 1-year high close of $295.03 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $3.88, revenue est. $18.4B).
As of the Nov 13, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABBV and SPY from Benzinga historical bars. Not investment advice.